Revelation Biosciences, Inc. (NASDAQ:REVB)
| Market Cap | $1.99M-85.3% |
| Revenue (ttm) | $0 |
| Net Income | -$12.16M-49.6% |
| EPS | -$37.63+66.1% |
| Shares Out | 569.06K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,801 |
| Open | $3.71 |
| Previous Close | $3.69 |
| Day's Range | $3.50 - $3.80 |
| 52-Week Range | $3.08 - $40.60 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Apr 1, 2027 |
About REVB
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Next catalysts
- Apr 1, 2027Earnings report
$REVB stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in REVB holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by REVB's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
REVB Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New REVB patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to REVB from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from REVB’s recent data — informational, not investment advice
What’s Behind the Score
News check: Multiple concrete announcements of accelerated development plans, strategic partnerships, and positive financial results suggest bullish momentum entering an important period.
